key: cord-0894399-anot0b8z
authors: Li, Weizheng; Dong, Yongxue; Lei, Xianmei
title: No Evidence Indicates Famotidine Reduces the Risk of Serious Disease in COVID-19 Patients After Propensity Score Matching: Meta-Analysis and Systematic Reviews
date: 2021-09-01
journal: Dig Dis Sci
DOI: 10.1007/s10620-021-07214-9
sha: b56c2d3171d9f026753f898b0974dcb76fddccea
doc_id: 894399
cord_uid: anot0b8z

nan

Propensity Score Matching, the correlation between the use and non-use of famotidine in COVID-19 patients with the serious illness was not statistically significant, and the P-value is over 0.05 (Figs. 1, 2) .

Finally, the article by Freedberg et al. was an observational study that cannot exclude the possibility of unmeasurable confounding factors or hidden biases and performed insignificant differences between use and non-use of famotidine reducing the risk of serious disease in COVID-19 patients [3] . This was a single-center study, which may limit the generality of the findings [3] . Zhou et al. indicated that the use of famotidine may increase the risk of severe COVID-19 disease after Propensity Score Matching [2] . However, Mather et al. believed that the matching of propensity scores to adjust for age differences between famotidine and non-famotidine patients did not change the significance of the differences in mortality or combined mortality and intubation in the analysis [4] . Similarly, Shoaibi et al. stated that with real-world data from a large multi-agency hospital database, no evidence has been found that famotidine used in hospitalized COVID-19 patients reduced the risk of death compared with non-users [5] . To better understand these contradictions, we analyzed the data of these articles through meta-analysis. Our work shows no significant statistical difference between use and non-use of famotidine reducing the risk of serious disease in COVID-19 patients after Propensity Score Matching. One more thing worth noting is, due to the suddenness of the epidemic, many studies cannot be performed ordinarily. This is susceptible to many complex factors. Therefore, more studies with Propensity Score Matching are needed in the future to further shed light on this problem.

In this issue of Digestive Diseases and Sciences, Dr. Li and colleagues reported an updated meta-analysis investigating the association between famotidine and risk of serious disease in Coronavirus Disease 2019 (COVID-19) patients in response to our original meta-analysis with same topic of interest [1] .

Dr. Li and colleagues included four original studies with effect values after Propensity Score Matching, which also found that famotidine use was not associated with change of the risk of serious disease in COVID-19 patients, similar to our conclusion [1] . Li et al. excluded one study conducted by Freedberg et al [2] . In our meta-analysis, this study was excluded for sensitivity analysis which proved the stability of our results, as excluding this study did not significantly change our result [1] . This updated meta-analysis performed by Dr. Li and colleagues provided further evidence that famotidine use was not associated with either reduced or increased risk of severe disease in COVID-19 patients. However, one limitation that shared both by the meta-analysis conducted Dr. Li and his colleague and our meta-analysis was the small number of included studies due to the limited number of original studies conducted so far. Another unsolved question, as pointed out by Dr. Malone, is whether higher dose of famotidine can provide clinical benefits [6] . However, its efficacy and effectiveness in higher dose when used as a single agent for treatment of COVID-19 can hardly be known, as most studies applied multi-agent strategies when treating COVID-19 patients [6] . Thus, future studies will also need to investigate the effects of different famotidine doses on COVID-19.

In addition to famotidine, proton pump inhibitors (PPIs) are also widely used in clinical practice. Recent meta-analysis found that PPIs might be associated with worse composite poor outcome, as well as an increased risk of severe disease and secondary infection in COVID-19 patients [7, 8] . Considering the current available evidence, it might be more reasonable to choose famotidine over PPIs for COVID-19 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by-nc/4. 0/.

Does famotidine reduce the risk of progression to severe disease, death, and intubation for COVID-19 patients? A systemic review and meta-analysis

Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study

Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study

Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19

Comparative effectiveness of famotidine in hospitalized COVID-19 patients

More than just heartburn: does famotidine effectively treat patients with COVID-19?

Will proton pump inhibitors lead to a higher risk of COVID-19 infection and progression to severe disease? A meta-analysis

Proton pump inhibitor on susceptibility to COVID-19 and its severity: a systematic review and meta-analysis